Our Pipeline
Overview
NEOK is taking a thoughtful approach to building a novel pipeline of bispecific ADCs by pursuing clinically validated targets, while balancing high expression, selectivity, and target-related safety signals.
Targeting Significant Unmet Treatment Needs
Our bispecific ADC portfolio currently consists of two assets designed to target proteins broadly expressed across tumor types with significant unmet needs, with an initial focus on thoracic, gastrointestinal and gynecological cancers which are known to be sensitive to Topo-1 inhibition. NEOK is one of the first companies pursuing these targets using this bispecific approach.
NEOK001
NEOK001 is a bispecific ADC targeting ROR1 and B7-H3 which has demonstrated superior in vivo efficacy compared to monovalent ADCs.
​
The dual targeting capabilities of NEOK001 support its potential across several large patient populations and offer an opportunity to demonstrate enhanced efficacy and safety against competitive ADCs that only target ROR1 or B7-H3 singularly.
NEOK002
NEOK002 is a bispecific ADC targeting EGFR and MUC1 which has demonstrated superior in vivo efficacy compared to monovalent ADCs.
​
The dual targeting capabilities of NEOK002 support its potential across several large patient populations and offer an opportunity to demonstrate enhanced efficacy and safety against competitive ADCs that only target EGFR or MUC1 singularly.
Asset (targets)
Development Candidate
IND-Enabling
IND
Phase I
NEOK001
(ROR1, B7-H3)
NEOK002
(EGFR, MUC1)
Mid-26
Mid-26
Q1’26
Q1’26